Troluce Capital Advisors LLC Viking Therapeutics, Inc. Transaction History
Troluce Capital Advisors LLC
- $1.91 Billion
- Q4 2024
A detailed history of Troluce Capital Advisors LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Troluce Capital Advisors LLC holds 172,300 shares of VKTX stock, worth $5.87 Million. This represents 0.36% of its overall portfolio holdings.
Number of Shares
172,300Holding current value
$5.87 Million% of portfolio
0.36%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding VKTX
# of Institutions
466Shares Held
65.8MCall Options Held
5.84MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$347 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$205 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$168 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$88.4 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$73.5 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.61B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...